Acute leukemia during pregnancy: a single center experience with 23 cases, 2012–2022 and literature review
Our findings suggest that for non-M3 AL patients can sometimes be managed during pregnancy. For M3 patients, early treatment potentially yield favorable outcomes for both the mother and fetus, using ATRA-based regimens without arsenic trioxide (in the second and third trimester) or standard chemotherapy (in the second trimester) may be considered a treatment option.
Authors
- Jiamin Guo (ORCID: https://orcid.org/0000-0002-8441-1266)
- F. Chen
- Dongzheng Gai
- Cong Chen (ORCID: https://orcid.org/0000-0003-0875-7473)
- Kaixuan Zhang (ORCID: https://orcid.org/0000-0003-1065-0595)
- Yi Liu (ORCID: https://orcid.org/0000-0002-1058-0382)
- Xielan Zhao
- Steven T. Rosen
- Wei Liu
- Xiao Fu
Institutions
- Central South University (CN)
- Changzhi Medical College (CN)
- City of Hope (US)
- National Clinical Research (US)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Annals of Medicine
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1080/07853890.2026.2626141
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00